z-1913661252

Z1913661252 is a novel riboswitch activator, binding ZTP riboswitches, and activating transcription more strongly than ZMP in vitro.

LFS-829 is a a small-molecule antagonist of exportin-1. LFS-829 showed low-range nanomolar activities. Oral administration of LFS-829 can significantly reverse the pathological features of colitis model mice. LFS-829 can attenuate dual NF-κB signaling and the Nrf2 cytoprotection pathway via targeting exportin-1 in colitis mice. Moreover, LFS-829 has a very low risk of cardiotoxicity and acute toxicity. LFS-829 holds great promise for the treatment of colitis and may warrant translation for use in clinical trials.